

1 **Supporting Information**

2 **SI Materials and Methods**

3 **Proteomics Sample preparation.** UTI89 and UTI89 $\Delta$ *qseC* cultures were grown statically in  
4 LB, at 37C for 18h. A total of 4 ml from each culture was pelleted at 6,000rpm for 7 minutes, the  
5 cell pellet was solubilized in lysis buffer (Tris-HCl pH 8.5 (30 mM), 7 M urea, 2 M thiourea, and  
6 4% CHAPS), and the total protein content was determined using the Advanced Protein Assay  
7 (Cytoskeleton, Inc.). A total pool was generated using equal amounts of each sample to represent  
8 all proteins found in the study. An aliquot containing 50  $\mu$ g of protein from each sample was  
9 diluted to 50  $\mu$ l with lysis buffer (Tris-HCl pH 8.5 (30 mM), 7 M urea, 2 M thiourea, and 4%  
10 CHAPS) and labeled with 400 pmol of charge-matched cyanine dyes Cy2, or Cy5 as previously  
11 described (Alban *et al.*, 2003). The total pool sample was labeled using Cy3. All labeling  
12 reactions were carried out for 45 min at 47°C, protected from light and quenched with 10 nmol of  
13 lysine for 10 min.

14 **2-DE and imaging.** Each combined tripartite-labeled sample (450  $\mu$ l final volume) was  
15 rehydrated into 24 cm, 3–10 NL IPG strips (GE Healthcare) under low voltage (100 V) for 12 h,  
16 followed by IEF using a Protean IEF cell (Bio-Rad) for a total of 65.5 kVh (using a three-step  
17 voltage protocol: 500 V and held for 500 Vh, 1000 V and held for 1000 Vh, 8000 V, and held for  
18 64000 Vh). After focusing, proteins were reduced by placing the IPG strips in 10 ml of  
19 equilibration buffer (10 ml, 50 mM Tris (pH 8.8), 6 M urea, 30% glycerol, 2% SDS,  
20 bromophenol blue) containing DTT (50 mg) for 15 min at room temperature. The proteins were  
21 then alkylated by adding iodoacetamide (600 mg in 10 ml of equilibration buffer). IPG strips  
22 were then rinsed with 1X SDS running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) and  
23 layered on 10-20% polyacrylamide gels and sealed with agarose (1% w/v in running buffer).

24 Commercially prepared gels (Jule, Inc.) were cast between low-fluorescence glass plates using  
25 bind-silane (GE Healthcare) to attach the gel to one plate as *per* the manufacturer's instructions.  
26 Second-dimension SDS-PAGE separation was carried out on all gels simultaneously using 5  
27 W/gel for the first 15 min followed by 1 W/gel for 17 h with circulating buffer (20°C) in the  
28 lower buffer chamber. Images of the labeled proteins in each gel were generated using a  
29 Typhoon Imager (GE Healthcare) and the following excitation/emission wavelengths for each  
30 dye (488/520 nm for Cy2, 520/580 nm for Cy3, and 620/670 nm for Cy5). After image  
31 generation, the gels were fixed (33% ethanol, 7.5% acetic acid) for 2 h, rinsed with deionized  
32 water and stored in water-filled, sealed bags at 47°C.

33 **Gel image analysis and digestion.** ImageQuant (Molecular Dynamics) software was used to  
34 crop the gel images. The DeCyder (v. 6.5) DIA (difference in-gel analysis) module was used to  
35 identify gel feature boundaries and calculate abundance ratios using a normalization algorithm  
36 that was applied as previously described (Alban et al., 2003, Karp *et al.*, 2004). Standard  
37 parameters were used to determine boundaries estimating 10,000 spots per image. Gel artifacts  
38 were removed by software from each gel image using a peak volume filter set at 10,000.  
39 Additional gel artifacts (*e.g.* water spots, dust particles) were excluded manually. Images were  
40 compared across multiple gels using the DeCyder BVA (Biological Variation Analysis) module.  
41 This analysis matched spots in the pool images from each gel, using this sample as a quantitative  
42 reference for protein spots in the remaining images allowing quantitative comparison of spots in  
43 all images in the experiment. The DeCyder Extended Data Analysis (EDA) module was used to  
44 perform t-test analysis. Fifty spots were selected based on their P value (<0.005) and fold change  
45 (relative to wt) and excised robotically (ProPic, Genomic Solutions). Proteins in the gel pieces  
46 were digested in situ with trypsin (Havlis *et al.*, 2003), and analyzed by mass spectrometry.

47 **Mass Spectrometry Analysis.** Samples were processed and analyzed using a nanoflow (200  
48 nl/min) pulse-free liquid chromatograph, interfaced to a quadrupole time-of-flight mass  
49 spectrometer (Q-STAR XL, Applied Biosystems) using a PicoView system (New Objective,  
50 Woburn, MA), or nano-reversed-phase HPLC interfaced to an electrospray-linear ion trap-  
51 Fourier transform ion cyclotron mass spectrometer (LTQ-FT, Thermo-Finnigan) operated as  
52 previously described (King *et al.*, 2007). The MS and MS/MS data were collected in the profile  
53 mode. The “raw” files were processed using MASCOT Distiller, version 2.1.1.0 (Matrix Science,  
54 Oxford, U.K.) and searched using MASCOT version 2.2.04 against the 20080125 Uniprot  
55 protein database. The resulting DAT files were imported into Scaffold, ver. 2.02.03 (Proteome  
56 Software, Portland, OR) to identify proteins with greater than or equal to 95% confidence and to  
57 determine the spectral counts for each protein. An in-house program combined data from  
58 MASCOT searches and Scaffold output to generate the peptide tables presented in  
59 supplementary data.

60 **Metabolic Phenotype Microarrays.** Bacteria from LB agar plates were resuspended into 10 ml  
61 of IF-0a GN/GP Base IF (Biolog Inc.) to an 85% transmittance. PM media were prepared  
62 according to the manufacturer’s instructions, using sodium succinate/ferric citrate as the carbon  
63 source for plates PM3-5. Niacin was added to all media (10 µg/ml). Microplates PM1-PM5  
64 (Biolog Inc.) were inoculated with 100 µl of the corresponding PM media containing the  
65 bacterial suspension and incubated at 37°C for 48h (Omnilog Incubator, Biolog). Optical density  
66 measurements were obtained at 15 min intervals (OmniLog PM DC 1.30.01 software). Data  
67 analysis and kinetic plots generation were performed using OmniLog PM software. Average plot  
68 height was used for data comparisons and a difference >20 was set as the significance threshold  
69 per the manufacturer’s instructions.

70 **Enterobactin quantitation.** Enterobactin levels were quantified by liquid chromatography-mass  
71 spectrometry (LC-MS) as described by Henderson *et al* (Henderson *et al.*, 2009).

72

### 73 **SI Results**

74 Fig. S1 shows the results of microarray and proteome profiling focusing on membrane transport.

75 Fig. S3 shows the different stress response systems the expression of which is altered in the  
76 absence of the QseC sensor.

77 **Deletion of *qseC* affects iron homeostasis.** Among the dysregulated genes in UTI89 $\Delta$ *qseC*, 5%  
78 are involved in iron homeostasis, including siderophore biosynthesis and transport, transport of  
79 free iron, and scavenging of iron from host proteins (Figure 3A, Table SI). Iron is essential for  
80 growth and bacteria have developed numerous iron uptake systems to ensure sufficient iron  
81 acquisition from diverse environments (Andrews *et al.*, 2003). UTI89 expresses 3 siderophore  
82 systems dedicated to the production of yersiniabactin, enterobactin, and salmochelin (Henderson  
83 *et al.*, 2009). Previous studies demonstrated that several iron acquisition systems are upregulated  
84 in UPEC during infection (Reigstad *et al.*, 2007) and showed a correlation between increased  
85 production of yersiniabactin/salmochelin and increased fitness of UPEC during UTI (Henderson  
86 *et al.*, 2009).

87 In contrast to wt UTI89, UTI89 $\Delta$ *qseC* had increased expression of genes related to  
88 enterobactin synthesis (*entBCE* and *entF*) and transport (*fepCG*) (Fig. S2A), suggesting that the  
89 siderophore profile of the *qseC* mutant is shifted towards increased enterobactin production. In  
90 addition, upregulation of shikimate biosynthetic genes like *aroF* and *pheA* (Geo Accession) also  
91 points to increased enterobactin production. We used mass spectrometry to measure enterobactin  
92 levels in the supernatants of UTI89 and UTI89 $\Delta$ *qseC* grown statically over an 18h time course.

93 This analysis revealed a consistent lag in enterobactin synthesis in UTI89 $\Delta$ *qseC* during the first  
94 6h of growth (65% reduction) compared to wt UTI89 (Fig. S2B). However, by 18h of growth  
95 enterobactin levels in UTI89 $\Delta$ *qseC* were higher than wt, consistent with the observed  
96 upregulation of the corresponding enterobactin biosynthesis genes (Fig. S2B). Thus, deletion of  
97 *qseC* dysregulates siderophore expression and could interfere with iron acquisition, influencing  
98 other iron import/export systems. Indeed, our analyses showed that ferrous iron importers  
99 (*sitABCD*) and hemin uptake systems (*chuAS*, *chuXW*) (Andrews et al., 2003) were upregulated  
100 in UTI89 $\Delta$ *qseC*, whereas, genes associated with iron export (*tsx*, *ompW*) (Lin et al., 2008) were  
101 downregulated (Fig. S2A).

102 Interestingly, the *iscRSUA*, *hscA*, and *fdx* genes (important for generation of [Fe-S]  
103 clusters required for the activity of several proteins involved in electron transfer, catalysis and  
104 regulatory processes mainly in response to the oxidation status of the cell (Andrews et al., 2003))  
105 were highly upregulated in UTI89 $\Delta$ *qseC* (Fig. S2A). IscR is an [2Fe-S]-containing regulator  
106 (Table SII), which functions as an *iscRSUA* repressor when [Fe-S] clusters exceed the cellular  
107 requirements (Andrews et al., 2003). Given that *iscRSUA* expression is elevated, our data  
108 indicate that IscR is found in its apo-form, suggesting low [Fe-S] cluster levels. These results  
109 indicate that UTI89 $\Delta$ *qseC* behaves as if it is starved for iron. As iron availability is limited in the  
110 host, these impaired responses to iron by UTI89 $\Delta$ *qseC* argue that a major role of QseBC is to  
111 optimize iron acquisition during pathogenesis.


112

113

114

115

116 **Supplementary Figures and legends**



117

118 **Fig. S1.** Membrane transporters affected in the *qseC* deletion mutant. Differential expression of  
 119 factors implicated in membrane transport captured by transcriptional (graph) and proteomics  
 120 (table inset) analyses.

121

122

123

124


125

126

127

128

129




130

131 **Fig S2.** Absence of QseC interferes with iron homeostasis. A) Relative expression patterns of  
 132 iron-related genes in the *qseC* deletion mutant as determined by microarray. B) Effects of the  
 133 *qseC* deletion on production of linear enterobactin captured by LC-MS/MS. A representative of 3  
 134 independent experiments is shown.

135

136



137

138

139

140 **Fig. S3.** Stress-responses are dysregulated in the *qseC* deletion mutant. Aberrantly expressed

141 stress-related factors captured by (A) transcriptional and (B) proteomics analyses.

142

143

144

145

146

147


148

149

150

151





153

154

155 **Fig. S4.** The gene expression effects upon *qseC* deletion are independent of growth media and  
 156 conditions. Graphs depicting increased *qseB* and *aceB* expression in: A) UPEC  $\Delta qseC$  grown  
 157 static in LB media, B) UPEC  $\Delta qseC$  grown static in human urine, and C) EHEC  $\Delta qseC$  grown  
 158 shaking in DMEM media, as measured by qPCR analyses. Relative fold change was determined  
 159 by normalizing qPCR values to wt UTI89. A representative of three independent experiments is  
 160 shown in each panel.

161

162

163

164

165

166 **Supplementary Table Titles**

167

168 **Table S1.** Transcriptional regulators with altered expression in the absence of QseC

<b>Gene</b>	<b>Locus</b>	<b>Fold-change relative to wt</b>	<b>Regulatory function</b>
<u>Upregulated Targets</u>			
<i>ygiV</i>	UTI89_C3448	527159.23	Hypothetical transcriptional activator
<i>ygiX</i>	UTI89_C3450	531.1	QseB response regulator
<i>pyrI</i>	UTI89_C4850	29.55	Pyrimidine ribonucleotide biosynthesis
<i>sfaB</i>	UTI89_C1108	7.95	S fimbrial switch regulatory protein
<i>phpB</i>	UTI89_C0641	5.33	Putative regulator of metabolism
<i>pspC</i>	UTI89_C1576	4.89	Putative activator of <i>psp</i> expression
<i>rstA</i>	UTI89_C1796	2.63	Transcriptional regulator, <i>csgD</i> repressor
<i>yfiE</i>	UTI89_C2899	2.61	Hypothetical transcriptional regulator
<i>iscR</i>	UTI89_C2853	2.49	Transcriptional repressor involved in type 1 dependent biofilm formation
<i>yhdM</i>	UTI89_C3737	2.35	Zn(II)-responsive regulator of ZntA
<i>yedW</i>	UTI89_C2168	2.23	Putative TCS response regulator
<i>yhdL</i>	UTI89_C3736	1.92	Putative regulator
<i>yfhA</i>	UTI89_C2873	1.81	QseF response regulator
<i>rseC</i>	UTI89_C2892	1.42	Sigma-E factor regulatory protein RseC
<i>gppA</i>	UTI89_C4333	1.29	Enzyme; global regulatory functions
<i>cspA</i>	UTI89_C4097	1.2	Adaptation to cold-shock
<u>Downregulated targets</u>			
<i>agaR</i>	UTI89_C3560	-1.31	Putative DEOR-type transcriptional regulator of <i>aga</i> operon
<i>ymfK</i>	UTI89_C3004	-1.48	Putative phage repressor
<i>ycjZ</i>	UTI89_C0318	-1.49	Hypothetical transcriptional regulator
<i>asnC</i>	UTI89_C4298	-1.57	Asparagine biosynthesis regulator
<i>UC4931</i>	UTI89_C4931	-1.66	Putative response regulator
<i>gntR</i>	UTI89_C3946	-1.7	Regulator of Entner-Doudoroff

<i>metJ</i>	UTI89_C4523	-1.72	Methionine biosynthesis regulator
<i>argR</i>	UTI89_C3668	-1.77	Arginine biosynthesis regulator
<i>yedF</i>	UTI89_C2131	-1.89	SirA-like regulator
<i>ygiP</i>	UTI89_C3496	-2.01	Transcriptional activator TtdR
<i>ydjF</i>	UTI89_C1966	-2.22	Putative DEOR-type regulator
<i>UC1288</i>	UTI89_C1288	-2.23	Putative CI repressor of bacteriophage
<i>ybaO</i>	UTI89_C0475	-2.42	Hypothetical transcriptional regulator
<i>yeiL</i>	UTI89_C2437	-2.42	Regulatory protein
<i>xapR</i>	UTI89_C2736	-2.48	Xanthosine operon regulatory protein
<i>ybcM</i>	UTI89_C2134	-2.75	Hypothetical transcriptional regulator
<i>metR</i>	UTI89_C4392	-3.67	Methionine biosynthesis regulator
<i>ybdO</i>	UTI89_C0606	-3.96	Hypothetical transcriptional regulator
<i>sdiA</i>	UTI89_C2117	-3.99	Homolog of quorum sensing regulators
<i>gclR</i>	UTI89_C5031	-4.41	Putative regulator

169

170 **Table S2.** Proteomics raw data and protein identities (provided as a separate Excel spreadsheet).

171 **Table S3.** Metabolism-related microarray targets (provided as a separate Excel spreadsheet).

172 **Table S4.** Phenotypes gained and lost by EHEC 86-24 $\Delta$ *qseC* (provided as a separate Excel  
173 spreadsheet).

174 **Table S5.** Primers used in this study

175

Primer	Sequence (5'→3') <sup>1</sup>	Description
MHSH13_Forw	GACTCCTACGGGAGGCAGCA	<i>rrsh</i> : 16s rRNA
MHSH14_Rev	CAGCCATGCAGCACCTGTCT	<i>rrsh</i> : 16s rRNA
<i>yehD</i> _QRT_L	GAGATAATAACCCACGGTATCGTTGC	UTI89_C2385: <i>yehD</i> pilin
<i>yehD</i> _QRT_R	CTCGACCTATGATGGTGCAGTC	UTI89_C2385: <i>yehD</i> pilin
F17-like_QRT_L	TTATTCGTAGGCAATGGTATAATGGACC	UTI89_C4907: F17-like pilin
F17-like_QRT_R	CTTTTGGGGGAAGCGGATAATGGG	UTI89_C4907: F17-like pilin
<i>rstA</i> _qPCR_Forw	CTCGATAGCGATATGAACCACATCCTGG	UTI89_C1796: curli regulator

<i>rstA</i> _qPCR_Rev	GTAGGGAGTCAGAGACGTTTCCTGAATAC	UTI89_C1796: curli regulator
<i>csgD</i> _qPCR_Forw	GTTGTTTTTCCTGCTCAAAGTATCCTGCC	UTI89_C1161: curli regulator
<i>csgD</i> _qPCR_Rev	ACTAAACCTTCTTTGCAGGCGACAGCTC	UTI89_C1161: curli regulator
<i>aceB</i> _qPCR_Forw	GCGGTCTGCACTTGCCGGAAAAACATG	UTI89_C4573: <i>aceB</i> malate synthase
<i>aceB</i> _qPCR_Rev	CGCGGCAGATTAAAGCGATCTTCTGC	UTI89_C4573: <i>aceB</i> malate synthase

176

177

178 **SI References**

179

180 Alban, A., S. O. David, L. Bjorkesten, C. Andersson, E. Sloge, S. Lewis & I. Currie, (2003) A  
 181 novel experimental design for comparative two-dimensional gel analysis: two-  
 182 dimensional difference gel electrophoresis incorporating a pooled internal standard.  
 183 *Proteomics* **3**: 36-44.

184 Andrews, S. C., A. K. Robinson & F. Rodriguez-Quinones, (2003) Bacterial iron homeostasis.  
 185 *FEMS Microbiol Rev* **27**: 215-237.

186 Havlis, J., H. Thomas, M. Sebela & A. Shevchenko, (2003) Fast-response proteomics by  
 187 accelerated in-gel digestion of proteins. *Anal Chem* **75**: 1300-1306.

188 Henderson, J. P., J. R. Crowley, J. S. Pinkner, J. N. Walker, P. Tsukayama, W. E. Stamm, T. M.  
 189 Hooton & S. J. Hultgren, (2009) Quantitative metabolomics reveals an epigenetic  
 190 blueprint for iron acquisition in uropathogenic *Escherichia coli*. *PLoS Pathog* **5**:  
 191 e1000305.

192 Karp, N. A., D. P. Kreil & K. S. Lilley, (2004) Determining a significant change in protein  
 193 expression with DeCyder during a pair-wise comparison using two-dimensional  
 194 difference gel electrophoresis. *Proteomics* **4**: 1421-1432.

195 King, J. B., J. Gross, C. M. Lovly, H. Piwnica-Worms & R. R. Townsend, (2007) Identification  
 196 of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed  
 197 mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron  
 198 resonance mass spectrometry. *Rapid Commun Mass Spectrom* **21**: 3443-3451.

199 Lin, X. M., L. N. Wu, H. Li, S. Y. Wang & X. X. Peng, (2008) Downregulation of Tsx and  
 200 OmpW and upregulation of OmpX are required for iron homeostasis in *Escherichia coli*.  
 201 *J Proteome Res* **7**: 1235-1243.

202 Reigstad, C. S., S. J. Hultgren & J. I. Gordon, (2007) Functional genomic studies of  
 203 uropathogenic *Escherichia coli* and host urothelial cells when intracellular bacterial  
 204 communities are assembled. *J Biol Chem* **282**: 21259-21267.